Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06892925 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors

Study acronym: Spring
StatusActive, Not Recruiting
PhasePhase 2
Started2025-06-14
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 7 months later Apr 2026 → Dec 2026
See other at-risk trials from Eastern Hepatobiliary Surgery Hospital

Amendment history

2026-08-21
Study Status, Contacts/Locations v3
Enrollment closed, study ongoing
Primary completion pushed: 2026-04 → 2026-12
Study sitesdetails revised at 1 of 1 site
2025-07-07
Not Yet Recruiting→Recruiting Study Identification, Study Status, Oversight, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-05→confirmed 2025-06-14
Study sitesdetails revised at 1 of 1 site
Study titlerevised
QL1706 Combined withWith Lenvatinib and GEMOX Asas First - Line Treatment for Unresectable Biliary Tract Tumors
2025-03-26
Study Status v1
Completion date2028-04→2029-04
2025-03-18
Original filing
QL1706 Combined with Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors：A Single - Arm, Open - Label, Multi - Center, Prospective Phase II Clinical Trial (Spring Study)
Trial Details
NCT Number NCT06892925
Lead Sponsor Eastern Hepatobiliary Surgery Hospital
Conditions Biliary Tract Tumors
Enrollment 59 participants
Start Date 2025-06-14
Primary Completion 2026-12 (estimated)
Study Completion 2029-04 (estimated)
Updated on ClinicalTrials.gov 2026-08-24